Ireland-based Amarin Corp. PLC, with research operations based in the Mystic section of New London, has hired veteran biotech executive Paul E. Huff to bring its cardiovascular disease products to market.
In connection with Huff’s hiring as chief commercial officer, Amarin says it plans to establish a sales and marketing headquarters in New Jersey.
Huff has more than 25 years in pharmaceutical development and marketing at various firms, including Reliant Pharmaceuticals.
At Reliant, he led to market Reliant’s Omega-3 treatment, Lovaza, for lowering heart-harming triglycerides in the blood, Amarin said.
Amarin is in clinical development of two treatments for lowering triglycerides. It recently raised more than $100 million to continue drug development.
Â
